Accord enters Europe as Coherus stays quiet
Executive Summary
Accord Healthcare has capitalised on its market-leading European Commission approval for Pelgraz (pegfilgrastim) by making “meaningful sales” of the biosimilar neutropenia treatment in Germany within two days of launching. A trade introduction of Pelgraz in the UK is also underway, a company spokesperson told Generics bulletin.
You may also be interested in...
Intas Rumored As Another Suitor For Biogen’s Biosimilars Business
Reports have named Intas as another possible buyer for Biogen’s biosimilars business, following earlier rumors that Samsung Bioepis could be interested in a deal. Generics Bulletin spoke to both Intas and Biogen for their reaction.
Prestige And Intas Strike International Bevacizumab Deal
Prestige Biopharma and Intas Pharmaceuticals have announced a commercialization deal for Prestige’s HD204 proposed bevacizumab biosimilar, covering a range of territories including markets in the Americas, Europe, Africa and Asia.
Accord Seeks To Capitalize On Portfolio And Partnerships
Accord expects to maintain its historically high growth rates through a “holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’s ambitions in the CNS area.